172 related articles for article (PubMed ID: 20709754)
1. Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1.
Madeja M; Steffen W; Mesic I; Garic B; Zhorov BS
J Biol Chem; 2010 Oct; 285(44):33898-905. PubMed ID: 20709754
[TBL] [Abstract][Full Text] [Related]
2. Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.
Madeja M; Leicher T; Friederich P; Punke MA; Haverkamp W; Musshoff U; Breithardt G; Speckmann EJ
Mol Pharmacol; 2003 Mar; 63(3):547-56. PubMed ID: 12606761
[TBL] [Abstract][Full Text] [Related]
3. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
4. Regulation of antiarrhythmic drug propafenone effects on the c-type Kv1.4 potassium channel by PHo and K+.
Wang Z; Wang S; Li J; Jiang X; Wang N
J Korean Med Sci; 2009 Feb; 24(1):84-91. PubMed ID: 19270818
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
6. K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.
Slawsky MT; Castle NA
J Pharmacol Exp Ther; 1994 Apr; 269(1):66-74. PubMed ID: 8169853
[TBL] [Abstract][Full Text] [Related]
7. Comparative frequency-dependent effects of three class Ic agents, Org 7797, flecainide, and propafenone, on ventricular action potential duration.
Winslow E; Campbell JK
J Cardiovasc Pharmacol; 1991 Dec; 18(6):911-7. PubMed ID: 1725906
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of antiarrhythmic drugs flecainide and verapamil on fKv1.4ΔN channel currents in Xenopus oocytes.
Chen H; Zhang D; Chao SP; Ren JH; Xu L; Jiang XJ; Wang SM
Acta Pharmacol Sin; 2013 Feb; 34(2):221-30. PubMed ID: 23202797
[TBL] [Abstract][Full Text] [Related]
9. Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes.
Rolf S; Haverkamp W; Borggrefe M; Musshoff U; Eckardt L; Mergenthaler J; Snyders DJ; Pongs O; Speckmann EJ; Breithardt G; Madeja M
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jul; 362(1):22-31. PubMed ID: 10935529
[TBL] [Abstract][Full Text] [Related]
10. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
Decher N; Kumar P; Gonzalez T; Pirard B; Sanguinetti MC
Mol Pharmacol; 2006 Oct; 70(4):1204-11. PubMed ID: 16835355
[TBL] [Abstract][Full Text] [Related]
11. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
[TBL] [Abstract][Full Text] [Related]
12. Influence of non-P region domains on selectivity filter properties in voltage-gated K+ channels.
Immke D; Kiss L; LoTurco J; Korn SJ
Recept Channels; 1998; 6(3):179-88. PubMed ID: 10100326
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of the regulation of the voltage-gated potassium channel Kv2.1 by the modulatory α-subunit Kv9.3.
Kerschensteiner D; Monje F; Stocker M
J Biol Chem; 2003 May; 278(20):18154-61. PubMed ID: 12642579
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the interaction of tarantula toxin Jingzhaotoxin-III (β-TRTX-Cj1α) with the voltage sensor of Kv2.1 uncovers the molecular basis for cross-activities on Kv2.1 and Nav1.5 channels.
Tao H; Chen JJ; Xiao YC; Wu YY; Su HB; Li D; Wang HY; Deng MC; Wang MC; Liu ZH; Liang SP
Biochemistry; 2013 Oct; 52(42):7439-48. PubMed ID: 24044413
[TBL] [Abstract][Full Text] [Related]
15. Allosteric effects of external K+ ions mediated by the aspartate of the GYGD signature sequence in the Kv2.1 K+ channel.
Chapman ML; Blanke ML; Krovetz HS; VanDongen AM
Pflugers Arch; 2006 Mar; 451(6):776-92. PubMed ID: 16283201
[TBL] [Abstract][Full Text] [Related]
16. Rearrangements in the relative orientation of cytoplasmic domains induced by a membrane-anchored protein mediate modulations in Kv channel gating.
Lvov A; Greitzer D; Berlin S; Chikvashvili D; Tsuk S; Lotan I; Michaelevski I
J Biol Chem; 2009 Oct; 284(41):28276-28291. PubMed ID: 19690160
[TBL] [Abstract][Full Text] [Related]
17. A new K+ channel beta subunit to specifically enhance Kv2.2 (CDRK) expression.
Fink M; Duprat F; Lesage F; Heurteaux C; Romey G; Barhanin J; Lazdunski M
J Biol Chem; 1996 Oct; 271(42):26341-8. PubMed ID: 8824288
[TBL] [Abstract][Full Text] [Related]
18. Effect of propafenone on Kv1.4 inactivation.
Tian L; Jiang X; Rasmusson R; Wang S
J Physiol Biochem; 2006 Dec; 62(4):263-70. PubMed ID: 17615952
[TBL] [Abstract][Full Text] [Related]
19. Local anesthetic block of Kv channels: role of the S6 helix and the S5-S6 linker for bupivacaine action.
Nilsson J; Madeja M; Arhem P
Mol Pharmacol; 2003 Jun; 63(6):1417-29. PubMed ID: 12761353
[TBL] [Abstract][Full Text] [Related]
20. A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels.
Herrera D; Mamarbachi A; Simoes M; Parent L; Sauvé R; Wang Z; Nattel S
Mol Pharmacol; 2005 Aug; 68(2):305-16. PubMed ID: 15883204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
